Esophagectomy in Middle and Lower Thoracic Esophageal Cancer Patients Through Left Versus Right Transthoracic Approach

Phase 3

• Conditions: Esophageal Cancer
• Interventions: Procedure: Left thoracotomy; Procedure: Right thoracotomy

• Registration Number: NCT02448979
• Lead Sponsor: Chinese Academy of Medical Sciences

Brief Summary

Esophageal carcinoma is an aggressive malignant disease with poor prognosis. Surgical resection remains the most effective method for this malignancy. Although different approaches have been studied for the surgical resection of thoracic esophageal cancer, little evidence has been achieved due to lack of large scale multicenter randomized trials with regard to this issue: whether left transthoracic approach or right transthoracic approach is the optimal surgical approach for treating middle and lower thoracic esophageal cancer without upper mediastinal lymph node metastasis. The purpose of this study is to compare the postoperative local recurrence rate and long-term outcome of esophagectomy through left and right transthoracic approach in the middle and lower thoracic esophageal cancer patients without preoperative upper mediastinal lymph node metastasis.

Detailed Description

Esophageal carcinoma is an aggressive malignant disease with poor prognosis. Surgical resection remains the most effective method for this malignancy. As to the middle and lower thoracic esophageal cancer patients without upper mediastinal lymph node metastasis, the rational transthoracic approach either through right or left chest has not been clarified to date due to lack of large scale multicenter randomized trials. Although some randomized trials had been finished in single-center, there is no enough evidences that all lower and middle thoracic esophageal cancer patients should be surgically treated throuhg right chest approch. It is widely recognized that left thoracotomy approach(Sweet procedure) is not appropriate in the patients with upper mediastinal lymph node metastasis, because patients can benefit from the right thoracotomy approach, through which upper mediastinal lymph node can be dissected completely and may get a better long-term survival.Therefore,in this study, the enrolled patients are the middle and lower thoracic esophageal cancer patients without preoperative upper mediastinal lymph node metastasis by CT and/or ultrasound, and 10 hospitals will participate this study. Through comparison in postoperative complications and long term outcomes as well as locoregional recurrence between the left and right apppoach, hopefully we can answer the question whether the right or left transthoracic procedure is the optimal approach for treating middle and lower thoracic esophageal cancer patients without preoperative upper mediastinal lymph node metastasis.

Study Timeline

• Study Start: 2015-01
• Status Verified: 2015-05
• Study First Submitted: 2015-05-08
• Study First Submitted QC: 2015-05-17
• Last Update Submitted: 2015-05-17
• Study First Posted: 2015-05-20
• Last Update Posted: 2015-05-20
• Primary Completion: 2017-12
• Study Completion: 2019-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 800

Inclusion Criteria

1. Patients with histologically proved squamous cell esophageal cancer without any previous anti-tumor therapy;
2. The preoperative clinical TNM stage: cT1b-3N0-1M0;
3. Adequate function of heart, lung, liver, brain and kidney, which can tolerate esophagectomy either through left or right thoracotomy;
4. Without any preoperative distant metastases confirmed by preoperative examination such as chest and abdominal CT, brain MRI and bone scan or PET-CT;
5. No evidence showing suspicious upper mediastinal lymph node metastasis (short diameter of LN <0.8cm or shortest diameter / longest diameter <0.65) by the thoracic and abdominal CT and endoscopic ultrasonography(EUS).
6. Willing to participate the clinical trial and sign informed consent before being enrolled into clinical trail.

Exclusion Criteria

1. Non-squamous cell esophageal carcinoma or has any previous anti-cancer therapy before surgery;
2. The preoperative clinical TNM stage reaches: N2-3 or M1;
3. Inadequate cardiopulmonary, liver, brain and kidney function for tolerating the esophagectomy ;
4. Previous history of malignancy;
5. Unwilling to participate the clinical trial and refuse to sign informed consent

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Left thoracotomy	Left thoracotomy	Esophagectomy through left side transthoracic approach, with esophagogastric anastomosis above aortic arch and two-field lymphadenectomy (thoracic and abdominal lymph node)
Right thoracotomy	Right thoracotomy	Esophagectomy through right side transthoracic approach, with esophagogastric anastomosis above azygos vain arch or on the top of chest cavity and two-field lymphadenectomy (thoracic and abdominal lymph node)

Primary Outcome Measures

Name	Time	Method
Long term survival	5 years

Secondary Outcome Measures

Name	Time	Method
Disease free survival	5 years
Degree of lymph node dissection	3 years
Postoperative complications	3 years

Trial Locations

Locations (1)

Cancer hospital, Chinese Academy of Medical Sciences; 🇨🇳 Beijing, Beijing, China